User profiles for "author:Adnan Khattak"

Adnan Khattak

Edith Cowan University
Verified email at health.wa.gov.au
Cited by 4339

[HTML][HTML] Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer

J Tie, JD Cohen, K Lahouel, SN Lo… - … England Journal of …, 2022 - Mass Medical Soc
Background The role of adjuvant chemotherapy in stage II colon cancer continues to be
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …

[HTML][HTML] Adjuvant pembrolizumab versus placebo in resected stage III melanoma

AMM Eggermont, CU Blank, M Mandala… - … England Journal of …, 2018 - Mass Medical Soc
Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to
prolong progression-free and overall survival among patients with advanced melanoma. We …

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double …

AMM Eggermont, CU Blank, M Mandalà… - The lancet …, 2021 - thelancet.com
Summary Background The European Organisation for Research and Treatment of Cancer
(EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients …

Impact of the COVID-19 pandemic on cancer care: a global collaborative study

AR Jazieh, H Akbulut, G Curigliano, A Rogado… - JCO global …, 2020 - ascopubs.org
PURPOSE The COVID-19 pandemic affected health care systems globally and resulted in
the interruption of usual care in many health care facilities, exposing vulnerable patients with …

[HTML][HTML] Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325 …

AMM Eggermont, CU Blank, M Mandala… - Journal of clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE We conducted the phase III double-blind European Organisation for Research
and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab …

Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or …

AMM Eggermont, M Kicinski, CU Blank… - JAMA …, 2020 - jamanetwork.com
Importance Whether immune-related adverse events (irAEs) indicate drug activity in patients
treated with immune checkpoint inhibitors remains unknown. Objective To investigate the …

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

M Maio, K Lewis, L Demidov, M Mandalà… - The Lancet …, 2018 - thelancet.com
Background Systemic adjuvant treatment might mitigate the high risk of disease recurrence
in patients with resected stage IIC–III melanoma. The BRIM8 study evaluated adjuvant …

Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma

AMM Eggermont, M Kicinski, CU Blank… - NEJM …, 2022 - evidence.nejm.org
Background In the previously reported primary analyses of this phase 3 trial, 12 months of
adjuvant pembrolizumab resulted in significantly longer recurrence-and distant metastasis …

[HTML][HTML] Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

V Atkinson, A Khattak, A Haydon… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with …

KEYNOTE–D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma

GV Long, PF Ferrucci, A Khattak, TM Meniawy… - Future …, 2022 - Future Medicine
Despite improvements made with checkpoint inhibitor (CPI) therapy, a need for new
approaches to improve outcomes for patients with unresectable or metastatic melanoma …